CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,027,384 | +564.7% | 36,113 | +619.2% | 0.05% | +278.6% |
| Q2 2022 | $305,000 | -76.9% | 5,021 | -53.7% | 0.01% | -88.4% |
| Q1 2021 | $1,323,000 | +196.0% | 10,855 | +78.3% | 0.12% | +290.3% |
| Q2 2020 | $447,000 | -77.7% | 6,088 | -87.1% | 0.03% | -78.6% |
| Q1 2020 | $2,004,000 | -38.9% | 47,255 | -12.3% | 0.14% | -25.3% |
| Q4 2019 | $3,282,000 | +672.2% | 53,893 | +420.0% | 0.19% | +424.3% |
| Q3 2019 | $425,000 | -8.8% | 10,364 | +4.7% | 0.04% | -11.9% |
| Q2 2019 | $466,000 | -70.1% | 9,901 | -81.9% | 0.04% | -56.7% |
| Q4 2018 | $1,559,000 | +523.6% | 54,558 | +868.5% | 0.10% | +410.5% |
| Q3 2018 | $250,000 | -52.1% | 5,633 | -50.6% | 0.02% | -47.2% |
| Q1 2018 | $522,000 | +21.7% | 11,410 | -37.6% | 0.04% | -23.4% |
| Q4 2017 | $429,000 | – | 18,285 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |